Home › Arteriovenous Fistula › NCT06807099
WRAP North America
Prospective, Multicenter, Observational Study to Evaluate the Merit WRAPSODY® Cell Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion Within the Dialysis Outflow Circuit (WRAP North America)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Subject provides written informed consent for study participation. 2. Subject is male or female, with an age ≥ 18 years at date of enrollment. 3. Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 36 months. 4. Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon. 5. The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session. 6. Subject has stenosis or occlusion within the dialysis outflow circuit and is treated with WRAPSODY CIE in accordance with device instructions for use. Exclusion Criteria: 1. Subject has a planned surgical revision of access site. 2. Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia. 3. Subject has an uncorrectable coagulation disorder. 4. Known hypersensitivity to nickel or titanium. 5. Subject's hemodialysis access is anticipated to be abandoned within 6 months. 6. Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure. 7. Full expansion of a PTA balloon cannot be achieved during predilatation. 8. Device would be placed in the Superior Vena Cava 9. Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.
About the study
The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.
What is being tested
- Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE) (device)
Sponsor: Merit Medical Systems, Inc. · Participants: 250 · Started: Jul 31, 2025
Contact the study team
- Irene Coughlin · Phone: +1-385-766-9133
Official record on ClinicalTrials.gov — NCT06807099
Locations in the U.S.
| Alabama | Trinity Research Group, Dothan |
| Arizona | AKDHC Phoenix Surgery Center, Phoenix |
| California | Apex Research of Riverside, Riverside |
| Florida | American Access Care of Jacksonville, Jacksonville Sarasota Memorial Research Institute, Sarasota |
| Kentucky | University of Kentucky, Lexington |
| Rhode Island | American Access Care of Rhode Island, Providence |
| South Carolina | Medical University of South Carolina, Charleston Medical University of South Carolina, Orangeburg Spartanburg Medical System, Spartanburg |
| Texas | Texas Research Institute, Fort Worth Humble Vascular Surgical Center, Humble |
| Virginia | Sentara Vascular Specialists, Virginia Beach |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.